Eisai

part ways switch off track cancel end path
Biotech

Eisai's abandoned Enhertu challenger set to live on at BlissBio

Eisai once identified BB-1701 as a potential best-in-class molecule, citing its eribulin-based payload-linker technology as a differentiator.
Nick Paul Taylor Mar 21, 2025 7:20am
peeling an orange

Bristol Myers culls cell therapy deals with 2 biotechs

Dec 16, 2024 11:19am
Brain and money connected by a thread on a white background

Eisai pays $46M for Japan rights to Newron's schizophrenia med

Dec 13, 2024 8:37am
Manila folder with CONFIDENTIAL printed on it in red

Alzheimer's trials withheld brain injury risk disclosures: NYT

Oct 24, 2024 11:33am
craft scissors glue paper glue stick

Eisai plants molecular glue SEED with $1.5B biobucks deal

Aug 6, 2024 10:24am
programming code software computer

Eisai adopts Medidata's new clinical trial platform

Jul 25, 2024 3:05pm